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Abstract
Background. Adoptive T-cell therapy offers new options for cancer treatment. Clinical results suggest that T-cell persistence,
depending on T-cell memory, improves efficacy. The use of interleukin (IL)-2 for in vitro T-cell expansion is not straightfor-
ward because it drives effector T-cell differentiation but does not promote the formation of T-cell memory.We have developed
a cost-effective expansion protocol for chimeric antigen receptor (CAR)T cells with an early memory phenotype. Methods. Lym-
phocytes were transduced with third-generation lentiviral vectors and expanded using CD3/CD28 microbeads.The effects
of altering the IL-2 supplementation (0–300 IU/mL) and length of expansion (10–20 days) on the phenotype of the T-cell
products were analyzed. Results. High IL-2 levels led to a decrease in overall generation of early memory T cells by both de-
creasing central memory T cells and augmenting effectors. T memory stem cells (TSCM, CD95+CD45RO−CD45RA+CD27+)
were present variably during T-cell expansion. However, their presence was not IL-2 dependent but was linked to expansion
kinetics. CD19-CAR T cells generated in these conditions displayed in vitro antileukemic activity. In summary, production of
CAR T cells without any cytokine supplementation yielded the highest proportion of early memory T cells, provided a 10-
fold cell expansion and the cells were functionally potent. Discussion. The number of early memoryT cells in aT-cell preparation
can be increased by simply reducing the amount of IL-2 and limiting the length of T-cell expansion, providing cells with
potentially higher in vivo performance. These findings are significant for robust and cost-effective T-cell manufacturing.
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Introduction
Adoptive T-cell therapy, the administration of ex vivo
processed T cells, provides new treatment options for
refractory or advanced cancer [1]. Promising initial
clinical results demonstrated in melanoma with tumor-
infiltrating lymphocytes (TILs) [2] are now being
followed by genetically engineeredT cells. Use ofT-cell
receptor (TCR)–redirected T cells, e.g., in myeloma
targeting NY-ESO-1 [3], and especially, the remark-
able clinical success of chimeric antigen receptor (CAR)
T cells in B-cell malignancies [4], justify the
enthusiasm.
Nevertheless, clinical experience has shown that
determining the in vivo potency of T-cell products for
cancer is not straightforward.The durable control of
cancer is not the result of a single cell population or
a sole direct mechanism such as tumor cell killing.The
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durable control of cancer is rather due to a dynamic
anti-tumorT-cell response entailing different cell types
working in a temporally orchestrated manner during
treatment and disease control. Furthermore, effec-
tor function, e.g., tumor cell killing, is connected to
the short life expectancy on a per cell basis. Clinical
results suggest that T-cell persistence improves ther-
apeutic response [5,6] and this depends on telomere
length [7] and development of immunologic memory
[8–10].
Pre-clinical animal models have confirmed that
memory T cells are pivotal for in vivo anti-tumor ef-
ficacy. Terminally differentiated effector T cells with
the most potent cytotoxic functionality are not the
optimal therapeutic in the in vivo setting; instead, pure
preparations of less-differentiated memoryT cells with
greater in vivo proliferation and survival are more ef-
fective [11]. Thus, particular T-memory subsets with
greater proliferative capacity should be pursued
[11–14]: central memory T cells (TCM) instead of ef-
fector memory (TEM, both defined in Sallusto et al.
[15]), or even the most primitiveT memory stem cells
(TSCM, defined in Gattinoni et al. [12]).TSCM provide
not only superior potential for proliferation but also
self-renewal.
Studies in cancer-targeting adoptive T-cell therapy
have often focused solely on direct tumor cell killing
potency [16]. However, there is increasing evidence
for the importance of CD4+ cells in therapeutic T-cell
products. CD4+ T cells may have several roles in cancer
treatment provoking bystander immunity, support-
ing the activation of CD8+ cells as well as directly
inhibiting tumor growth [17]. In the tumor milieu
CD4+ cells have also shown to enhance the recruit-
ment, proliferation and cytotoxic function of CD8+ cells
[18]. Furthermore, in one clinical study T-cell per-
sistence and clinical efficacy were associated with the
presence of both less-differentiated T memory (TM)
cells as well as CD4+ T cells in the cell product [10].
Interestingly, CD4+ cells are indispensable for func-
tional CD8+ memory formation in mice [19,20]. It is
not known if the indicated CD4+ importance for clin-
ical efficacy was linked to memory formation.
In vivo,T-cell proliferation typically only takes place
during an immune response and thus T-cell activa-
tion, proliferation and effector/memory differentiation
are tightly coupled [21]. In vitro T-cell expansion is
achieved with signals mimicking normal T-cell acti-
vation [1]. Signaling through CD3 and CD28 in vivo
provokes autonomous IL-2 production by the acti-
vated T cells, which is central to clonal expansion.
Likewise, T-cell expansion in vitro is also character-
istically boosted with interleukin (IL)-2, “the T-cell
growth factor.” However, IL-2 drives T cells toward
effector differentiation at the expense of memory cell
formation [21]. Both IL-2 signaling strength and du-
ration are known to affect CD8 memory T-cell
development [22]. Furthermore, excessive stimula-
tion during in vitro expansion may lead to cell
exhaustion [23], yielding less potentT cells for therapy.
Thus, generation of effective T-cell based cancer ther-
apeutics requires a delicate balance between the final
cell dose and the quality of the cells.
Currently, several approaches have been pro-
posed for increasing the proportion of less-differentiated
T cells.The replacement of IL-2 with IL-7, IL-15 and
IL-21 uses the concept of physiological homeostatic
T-cell proliferation [24].This favors early memoryT-cell
generation from normal donors [25–27] as well as from
cancer patient–derived cells [28] and improves in vivo
anti-tumor functionality in pre-clinical models
[11,29,30]. Clinical evidence is pending but prelim-
inary results in four melanoma patients showed only
limited persistence of GD2-targeted CAR T cells ex-
panded using IL-7 and -15 [31]. Selection of more
primitive starting T-cell populations prior to in vitro
expansion [14] and use of signaling inhibitors that
prevent effector differentiation [32] are other strate-
gies for increasing the number of less-differentiated
T cells for adoptive T-cell therapy.
Increasingly sophisticated cell manufacturing
methods have been developed to achieve product re-
producibility and high efficiency. Multistep
manufacturing procedures may be more vulnerable and
could hinder the reproducibility of the manufactur-
ing method, perhaps leading to situations where the
patient will not receive the needed cell therapy product.
Each manufacturing step and production material in-
cluded in the method increases substantially the labor
needed to fulfill the Good Manufacturing Practice
(GMP) requirements because all the raw materials used
need to be controlled as well. This ultimately affects
the overall production costs and the cost-effectiveness
of the treatment.
In this work we investigated if T cells with pre-
ferred early memory phenotypes could be expanded
without cytokine supplementation and extra manip-
ulation. We have dissected the relative contributions
of simple in vitro cell expansion conditions (IL-2 con-
centration, the length of expansion) to the cell
composition ofT-cell product and therapeutic potency.
We pose that an optimal cancer-targetingT-cell product
encompasses appropriate subpopulation heterogene-
ity, providing (i) rapid killing efficiency (activated CD8+
effectors), (ii) CD4+ T cells and (iii) a considerable
proportion of less-differentiated, early memoryT cells.
In vitro functional studies were performed to assess
the functional significance of these results in the context
of adoptive T-cell therapy. In this study we have de-
veloped an effective and leanT-cell expansion protocol
that can be applied to the production of clinically
potent CAR T cells.
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Materials and methods
T-cell expansion
Peripheral blood mononuclear cells (PBMC) from
10 healthy blood donors were isolated from buffy
coats and from two leukemia patients from fresh
whole blood samples by density gradient centrifuga-
tion using Ficoll-Paque Premium (GE Healthcare).
Informed consent was obtained and the study and
the use of human material were approved by the
institutional review boards at the Finnish Red Cross
Blood Service and the Hospital district of Helsinki
and Uusimaa. Either fresh or cryopreserved cells
were magnetically enriched for T cells and activated
using Dynabeads Human T-Expander CD3/CD28
(Life Technologies) at a 3:1 bead to cell ratio. Cell
expansion was conducted in small-scale cultures in
X-VIVO 15 (Lonza) with 5% human AB serum
(Gemini or Seralab) starting with a cell density of
1 × 106/mL. Expansions from individual donors were
cultured in parallel under five different IL-2 (Proleukin,
Novartis) concentrations (0, 5, 20, 100 and 300 IU/
mL). From the third day onward, the cell density
was adjusted to 0.5 × 106/mL with IL-2–supplemented
culture media every 2–3 days.
Flow cytometry
Prior to phenotyping, the cells were fixed with
paraformaldehyde. The following antibodies from
BD Biosciences were used for staining: anti-CD3-
fluorescein isothiocyanate (FITC), R-phycoerythrin
(PE), BV510 (clone UCHT1) or FITC from Miltenyi
Biotec (clone BW264/56), CD4-peridinin chloro-
phyll protein-cyanin 5.5 (PerCP-Cy5.5) or BV510
(clone SK3), CD8-AlexaFluor647 or BV421 (clone
RPA-T8), γδTCR-PE (clone 11F2), CD56-
allophycocyanin (APC, clone B159), CCR7-PE (clone
150503), CD27-PerCP-Cy5.5 (clone M-T271),
CD45RA-APC (clone HI100), CD45RO-BV421
(clone UCHL1) and CD95-PE (clone DX2). B-cell
elimination from cell expansions was confirmed with
anti-CD19-PE (clone HIB19). Appropriate isotype
and fluorescence minus one (FMO) controls were
used. Memory T-cell subtypes were identified accord-
ing to the expression of CD27, CD45RA, CD45RO
and CD95 as explained in Table I. Altogether 11
expansions (nine healthy donors, two patients) were
phenotyped for memory T-cell status. Six of the
expansions were transduced with CAR, three with
green fluorescent protein (GFP) and two were T-cell
expansions without transduction.
All flow cytometric analyses were performed using
BD FACSAria IIu (BD Biosciences) and FlowJo
(version 7.6.5 or 10, TreeStar) software.
Construction of lentiviral vectors
The second-generation (2G) CD19-CAR (CD19-
scFv/CD28/z) was edited from the third-generation
(3G) construct (CD19-scFv/CD28/4-1BB/z [33]) by
removing the 4-1BB sequence. Self-inactivating 3G
lentiviral vectors (LVs) encoding CARs were gener-
ated by cloning the transgenes (GenScript) into LVs
with human phosphoglycerate kinase promoters [34].
Lentiviral transduction and analysis of CD19-CAR
expression
Two days after the activation, T cells were trans-
duced with LVs encoding either the 2G or 3G CD19-
CAR construct or GFP (data not shown) using a
multiplicity of infection of 10. CD19-CAR-expressing
cells were detected by flow cytometry using an
AlexaFluor647-conjugated F(ab′)2 fragment goat anti-
human immunoglobulin (Ig)G(H + L) (Jackson
Immunoresearch, Inc.). CAR-positive cells were gated
using untransduced or empty LV-transduced cells as
controls.The background was eliminated by subtract-
ing the percentage of positive cells in control samples
from the percentage of positive cells in CD19-CAR-
transduced samples. Control cells were cultured with
20 IU/mL IL-2.
B-cell lines
SupB-15 (CD19+ B-lineage acute lymphoblastic leu-
kemia [ALL]) cell line was purchased from ATCC.
NALM-6 (CD19+ B lineage ALL) was obtained from
Dr O. Lohi (University ofTampere, Finland). Cell lines
were cultured in RPMI-1640 medium (Life Tech-
nologies) supplemented with 10% fetal bovine serum
(LifeTechnologies), 100 IU/mL penicillin and 100 µg/
mL streptomycin (Life Technologies).
Functional characterization of CART cells
CD19-CART-cell functionality was tested using CD19-
expressing SupB-15 or NALM-6 B lineage ALL cells.
Cell proliferation, degranulation and cytokine secre-
tion assays were performed using cryopreserved and
Table I. Expression patterns used for T-cell subtype phenotyping.
Subtype
Naïve CD95− CD45RO− CD45RA+ CD27+
TSCM CD95+ CD45RO− CD45RA+ CD27+
TSCM-like CD95+ CD45RO+ CD45RA+ CD27+
TCM CD95+ CD45RO+ CD45RA− CD27+
TEM CD95+ CD45RO+ CD45RA− CD27−
TEff CD95+ CD45RO+ CD45RA+ CD27−
NOTE. Sequential differences in expression between subtypes are
shown by underlining.TSCM,TSCM-like and TCM cells represent less-
differentiated, early memory T cells.
TEff, effector T cell.
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thawed cells, and fresh cells were used for cytotoxicity
testing.
To measure proliferation in response to target cells,
CD19-CAR T cells were labeled with 5(6)-
carboxyfluorescein diacetate N-succinimidyl ester
(CFSE; LifeTechnologies), and co-cultured for 4 days
with NALM-6 at an effector-target cell ratio (E:T) of
10:1. CFSE dilution as a measure of proliferation was
detected using flow cytometry.
Cytometric bead array (CBA) was used to measure
the release of IL-2 and interferon (IFN)γ during a 1-day
1:1 co-culture of CD19-CAR T and NALM-6 cells.
The cytokine concentrations were measured from the
culture media using the BD CBA Human Soluble
Protein Master Buffer Kit, CBA IL-2 Flex Set and
CBA IFN-G Flex Set (BD Biosciences). Results were
analyzed using FCAP Array SoftwareVersion 3.0 (BD
Biosciences).
To measure degranulation in response to target
cells, T cells were incubated at 1:1 with NALM-6
targets for 4 h in the presence of a CD107a anti-
body (BD Biosciences, clone H4A3). Degranulating
T cells were identified by the surface expression of the
lysosomal-associated protein CD107a using anti-
CD107a-PE and flow cytometry.
Target cell killing efficacy was evaluated using the
calcein release cytotoxicity assay. CD19-expressing
SupB-15 or NALM-6 B-ALL target cells were labeled
with calcein-acetoxymethyl (LifeTechnologies) and co-
cultured at E:T ratios ranging from 0.3:1–30:1. After
a 4-h incubation, target cell killing efficiency was de-
termined by measuring the amount of fluorescent
calcein released into the culture media using a
FLUOstar Omega microplate reader (BMG Labtech).
Statistics
The differences between expansion conditions were
analyzed with Mann-Whitney test and unpaired t test
with two-sided P values. In analysis of CBA results,
means of multiple groups were compared using one-
way analysis of variance (ANOVA) andTukey multiple
comparisons test. Differences were considered statis-
tically significant when P < 0.05. Analyses were
performed using GraphPad Prism (version 6.07) soft-
ware.The dependence of cell lysis percentage on cell
ratios and IL-2 levels was modelled with a linear model
using R (version 3.3.1 [35]; see Supplementary file
for further details).
Results
T-cell expansion in low IL-2 concentration bolsters early
memoryT cells instead of effector phenotypes
IL-2 is a powerful cytokine inducing both clonalT-cell
expansion and effector differentiation.We asked if the
amount of exogenous IL-2 could be optimized for ex-
pansion of therapeuticT-cell preparations.T cells from
peripheral blood of nine healthy donors and two pa-
tients with leukemia were activated using microbeads
carrying CD3 and CD28 antibodies (Dynabeads) and
cultured with varying concentrations of exogenously
added IL-2 ranging from 0–300 IU/mL.T cells in most
expansions were transduced to express either CAR
(n = 6) or GFP (n = 3). On the tenth day of expan-
sion, memory T-cell status was analyzed (Figure 1A).
First, we analyzed the proportions of earlyTM cells, cor-
responding to TSCM, TSCM-like and TCM cells. Cultures
without or with only 5 IU/mL IL-2 had an 88%–89%
mean proportion of earlyTM (Figure 1B).When higher
IL-2 concentrations were used forT-cell expansion, the
proportion of earlyTM decreased, reaching 61% when
using 300 IU/mL IL-2. The transduction process did
not influence the memory T-cell composition as par-
allel untransduced control expansions gave similar results
(data not shown). Thus, the increment of IL-2 de-
creased the proportion of early memory T cells.
EachT memory cell subtype, includingTSCM,TSCM-like,
TCM andTEM cells, as well as effectorT cell (TEff), was
present in the expanded products on day 10, whereas
naïveT cells (CD95−) were absent after expansion. In-
creasing the amount of exogenously added IL-2 had
its most profound effects on two particular memoryT-cell
subtypes: it decreased TCM and increased TEff levels
(Figure 2).TCM decreased from the mean level of 32%
accomplished without any exogenous IL-2 to around
10% when using 20 IU/mL or more. Conversely, very
few TEff were detected in cultures with the two lowest
IL-2 conditions (0 and 5 IU/mL), but their mean pro-
portion increased with increasing exogenous IL-2,
reaching 27% at the highest concentrations.The pro-
portion of the most abundantT-cell subtype, theTSCM-like
population comprising roughly half of the cells, was not
substantially influenced by the amount of IL-2 supple-
mentation. Also, 100 IU/mL IL-2, considered here as
the current standard often used inT-cell production [36],
generated on average a 2.5-fold smaller proportion of
TCM and 5.5-fold more TEff compared with T cells ex-
panded without supplemental IL-2 (P = 0.04 and
P = 0.01, respectively; Figure 2).
In conclusion, these results demonstrate that an
essential shift toward early memoryT phenotypes can
be achieved by simply reducing the amount of IL-2
during in vitro T-cell expansion.
Instability of theTSCM population duringT-cell expansion
Cell products from altogether 11 donors (healthy n = 9;
patients n = 2) were phenotyped for their T-memory
status on day 10 of the expansion and, surprisingly,
six expansions (55%) were completely deficient in
TSCM (Figure 2). Absence of TSCM was not IL-2
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Figure 1. (A) A representative analysis of T memory phenotyping.T cells were expanded for 10 days under 0 IU/mL IL-2.The T-cell subset
composition was 0% naïve, 0% TSCM, 37% TSCM-like, 47% TCM, 15% TEM and 1% TEff. FMO controls were used for setting the gates. (B)
Low IL-2 concentration induces the generation of less-differentiated memory T cells. T cells from peripheral blood were activated and
expanded in vitro using CD3/CD28 microbeads with IL-2 concentrations ranging from 0–300 IU/mL. The percentages of early memory
T cells, defined as the sum of TSCM, TSCM-like and TCM cells, were analyzed on the tenth day of the expansion. Cells from five donors were
expanded in all the different conditions in parallel. Additional parallel expansions were done for 5–300 IU/mL IL-2 (0 IU/mL n = 5, 5 IU/
mL n = 6, 20 IU/mL n = 11, 100 and 300 IU/mL n = 10). Six expansions were lentivirally transduced with CAR and three with GFP. In
two expansions, the cells were not genetically modified. Results from individual expansions are shown along with means and 95% confi-
dence intervals. Transparent data points represent patient samples and solid data points healthy donor samples. The Mann-Whitney test
was used to calculate statistical significance (*P < 0.05).
Figure 2. Effect of IL-2 supplementation on memory T-cell subsets in the expanded T-cell products.The proportions of each T-cell subset
on the tenth day of in vitro expansion were plotted separately against the corresponding IL-2 conditions (0 IU/mL n = 5, 5 IU/mL n = 6,
20 IU/mL n = 11, 100 and 300 IU/mL n = 10). Results are shown along with means and 95% confidence intervals.Transparent data points
represent patient samples and solid data points healthy donor samples. The Mann-Whitney test was used to calculate statistical signifi-
cance (*P < 0.05).
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dependent, since expansions deficient for TSCM lacked
them under all IL-2 conditions (data not shown). Un-
fortunately, expansions that were also conducted
without exogenous IL-2 were, by chance, entirely de-
ficient for TSCM. The proportion of other early
T-memory subtypes, i.e.,TSCM-like and TCM cells, com-
pensated for the loss of TSCM. Hence, the total
proportion of early memory T cells was not signifi-
cantly lower in cultures where no TSCM were present.
Six expansions, three containing and three defi-
cient for TSCM at day 10, were cultured further and
analyzed again at day 20 (Figure 3). The three ex-
pansions that did not have detectable TSCM cells on
day 10 now had TSCM cells at a mean level of 23%
(using 20 IU/mL IL-2). In contrast, the mean TSCM
proportion decreased from 43% to 23% by day 20 in
those expansions that were already positive at day 10.
Contrasting with the instability of the TSCM popula-
tion, a longer expansion time led to a consistent
decrease in TSCM-like and TCM, and an increase in the
TEff populations (Figure 3).The size of theTEM subset
predominantly remained unchanged.
The reason for this variation in the TSCM subset
could not be identified but several method-related
issues were excluded (e.g., serum batch, culture
format [well vs flask], use of fresh vs cryopreserved
cells as starting material, laboratory deviations, and
type of genetic modification). However, a lower
cumulative fold expansion by day 10 was often
related to the absence of the TSCM subset at this time
point. These findings suggest that the presence of
TSCM cells may be linked to expansion kinetics.
These data emphasize the sensitivity of primary cell
culturing and elucidates the challenges in cell
manufacturing.
In summary, the TSCM population was not de-
tected in every expansion product at day 10. However,
T-cell cultures that first lacked these cells could bear
a prominent population during subsequent expansion.
A shorter in vitro expansion time yields a higher
proportion of early memoryT cells
Because we found that the proportion of TSCM could
change upon prolonged expansion, we next investi-
gated the effect of a longer expansion time on the yield
of cells with the desired early memory T-cell pheno-
type. Using IL-2 concentrations ranging from
0–300 IU/mL, an average 11- to 62-fold expansion of
the T-cell product was achieved during the 10-day
culture (Table II), and by day 20 of expansion the cells
reached 140- to 12 000-fold using 20–300 IU/mL IL-2
(Figure 4). Day 20 data is only available for cultures
where 20–300 IU/mL IL-2 was used, because the cells
cultured with less cytokine did not proliferate well
enough for testing.
Compared with 10 day-long cultures, the day 20
expansion cultures yielded an approximately two-
Figure 3. Change in memory T-cell subsets during in vitro T-cell expansion. Cells were phenotyped for their memory status on the tenth
and twentieth days of the expansion (n = 6; two CAR-transduced, two GFP-transduced and two untransduced). Lines connect results from
individual expansions, which are shown with the same symbols in every diagram. The transparent symbols in each plot represent expan-
sions that were negative for TSCM on day 10 (n = 3). Representative data from expansions with 20 IU/mL IL-2 is shown.
Table II. Summary of key determinants for 10 day in vitro T-cell expansion under different IL-2 conditions.
Early TM (%); mean
(min–max)
Cumulative fold expansion;
mean (min–max)
Total yield for early
TM; mean (min–max)
CD4+ (%); mean
(min–max)
Effector
function
No IL-2 88 (83–93) 11 (4–18) 9.6 (3.0–15) 63 (43–87) +
5 IU/mL IL-2 89 (81–96) 12 (3–21) 11 (2.4–19) 58 (26–88) +
20 IU/mL IL-2 77 (39–95) 39 (4–100) 27 (3.3–52) 43 (12–82) ++
100 IU/mL IL-2 74 (32–94) 60 (3–150) 37 (2.1–97) 61 (19–93) +++
300 IU/mL IL-2 61 (17–94) 62 (4–140) 31 (2.7–81) 67 (26–94) +++
NOTE. n = 5–12 depending on condition. The total yield for early memory T cells was calculated by multiplying the percentage of early
TM with the corresponding cumulative fold expansion.
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fold lower mean level of early memory T cells with
each tested IL-2 concentration (20–300 IU/mL;
Figure 5). Closer subtype analysis in this larger data
set confirmed the observations in Figure 3: longer ex-
pansion led to a decrease in both TSCM-like and TCM
proportions and increased TEff in all three IL-2 con-
ditions (Supplementary Figure S1). Of note, the TCM
population was practically lost from expansion cul-
tures by day 20.
These results indicate that, although the total yield
of cells is less, shorter in vitro culture may be desir-
able for clinical T-cell production because it generates
T cells with an early memory status.
High IL-2 concentration favors CD4+T cells but longer
expansion time promotes preponderance of CD8+ cells
The expanded cell products consisted solely of CD3
T cells (>98% on day 10). No γδ T cells were de-
tected, and both CD4+ and CD8+ cells were present
in all cultures under all conditions.The proportion of
CD4+ cells at day 10 varied considerably between ex-
pansions (e.g., proportion of CD4+ cells ranged from
12%–82% with 20 IU/mL IL-2; Figure 6 and Table II).
A high concentration of IL-2 led to a somewhat higher
Figure 4. Expansion kinetics for T cells cultured under different IL-2 conditions (0 IU/mL n = 5, 5 IU/mL n = 6, 20 IU/mL n = 12, 100
and 300 IU/mL n = 10). Individual expansions are shown on logarithmic scales. Cell expansion was conducted using CD3/CD28 microbeads.
The number of viable cells was determined with a hemacytometer and trypan blue exclusion on every other or third day.
Figure 5. Shorter in vitro culture generates T cells with an early
memory phenotype.The percentages of early memoryT cells (TSCM,
TSCM-like and TCM cells) were analyzed on the tenth (transparent
symbols, n = 10–11) and twentieth (black symbols, n = 6) day of
the expansions using 20–300 IU/mL IL-2. Results from individu-
al expansions are shown along with means and 95% confidence
intervals. Statistical significance was calculated using the Mann-
Whitney test (*P < 0.05).
Figure 6. Effect of IL-2 supplementation and expansion time on
the number of CD4+ cells. T cells expanded under different IL-2
conditions were analyzed for their CD4+ T-cell content at two time
points (day 10, transparent bars, and 20, solid bars). Data are from
five to 11 independent expansions depending on the time point and
experimental condition. Data for day 20 is only available for 20–
300 IU/mL IL-2 because the cells did not proliferate well enough
for testing when less IL-2 was added. Means with 95% confi-
dence intervals are shown, and the Mann-Whitney test was used
to calculate statistical significance (*P < 0.05).
IL-2 supplementation during in vitro T-cell expansion 695
fraction of CD4+. In contrast, longer expansion times
favored CD8+ over CD4+ cells (Figure 6). Under all
tested IL-2 conditions (20–300 IU/mL) there was a
2- to 4-fold decrease in CD4+ and a reciprocal in-
crease in CD8+ proportions from day 10 to day 20.
Thus, expansion time had major effect onT-cell popu-
lations by altering the cell balance toward CD8+ T-cell
dominance.
A small fraction of the expanded T cells gained
CD56 expression by day 20 of expansion (data not
shown).These cytokine induced killer (CIK)-type cells
comprised approximately 10% of the cell product, re-
gardless of the IL-2 concentration used (20–300 IU/
mL). Similar data have been reported by others but
already after 10 days of expansion [36].
In summary, the relative proportions of CD4+ and
CD8+ T cells in in vitro T-cell expansion are affected
by both the level of exogenous IL-2 and length of ex-
pansion. CD4+-enriched products can be generated
using a high concentration of IL-2 (≥100 IU/mL) for
about 1 week. On the other hand, a longer expan-
sion protocol yields products consisting predominantly
of CD8+ cells.
IL-2 concentration affects particularly the memoryT-cell
subtype distribution of CD4+ cells
We also asked if memory status was differently af-
fected among expanded CD8+ and CD4+ T cells. In
both populations the mean proportion of early memory
T cells was high on day 10 under different IL-2 con-
ditions, being 73%–91% for CD8+ (Supplementary
Figure S2A) and 66%–88% for CD4+ cells
(Supplementary Figure S2B). Use of high IL-2 con-
centration during expansion led to a decrease in early
memory T cells in both populations as already dem-
onstrated for total T cells (Figure 1B) but the
differences reached statistical significance only in the
CD4+ population. IL-2 induced TEff differentiation in
both CD8+ and CD4+ T cells and lower levels of IL-2
yielded higherTCM numbers at day 10 (Supplementary
Figure S3).
If the culture time was extended up to 20 days,
only 20%–40% of cells represented early TM sub-
types in both CD8+ and CD4+ cells when 20–300 IU/
mL IL-2 was used, and 60%–80% of the cells consisted
of TEM and TEff cells (n = 5, data not shown). At 20
days, increasing IL-2 concentration had a similar effect
to what was was seen already on day 10: high con-
centration of IL-2 (300 IU/mL) favored the generation
of higher proportions of TEff (66% and 64%, respec-
tively) within the CD8+ and CD4+ fractions, whereas
less TEff (50% and 38%, respectively) were gener-
ated using 20 IU/mL IL-2. Conversely, high IL-2
concentration led to reduced generation of early TM
cells.
In summary, exogenous IL-2 increment in the in
vitroT-cell expansion affects particularly CD4+ T-cell
memory distribution leading to less early memory T
cells and a preponderance of differentiated effector cells.
CD19-CART cells expanded under different IL-2
conditions had versatile in vitro effector functions and
were target-specific
CD19-CAR expression was analyzed at day 10 of
T-cell expansion (8 days post-transduction) using flow
cytometry (Figure 7A and 7B). The mean percent-
age of CAR-expressing cells was 52% (range, 8%–
89%), and the level of IL-2 supplementation had no
apparent effect on transduction efficiency. Both 2G
and 3G CAR constructs were successfully expressed
on primary human T cells.
Several assays were performed to analyze the impact
of varying IL-2 supplementation on the functional char-
acteristics of the CD19-targeted CAR T cells
(Figure 7). Buffy coats from three donors (donors 1–3)
were used to generate CAR T cells using the five dif-
ferent IL-2 concentrations (0–300 IU/mL), and the
resulting cells were then subjected to proliferation,
Figure 7. Lentivirally transduced T cells express CD19-CAR and demonstrate in vitro activity against B-ALL. Human primary T cells
were transduced with lentiviral vectors carrying 2G or 3G CD19-CAR-transgenes and expanded under IL-2 concentrations ranging from
0–300 IU/mL IL-2. (A) CAR expression at day 10 of T-cell expansion, mean percentages of CAR-expressing cells with 95% confidence
intervals are shown. The transparent data points represent 2G and solid data points 3G CAR (20 IU/mL IL-2 n = 9, others n = 6). (B) A
representative histogram of CAR expression on 3G CAR-transduced (dark) and untransduced control (transparent) T cells expanded under
20 IU/mL IL-2. (C) Proliferation activity of CFSE-labeled CAR-transduced T cells during a 4-day co-culture with CD19+ NALM-6 B-ALL
cells shown as percentages of proliferating cells. (D) Degranulation activity of NALM-6–stimulated CAR-transduced T cells shown as per-
centages of CD107a+ cells. (C–D) Results shown from CAR T cells generated from three donors, each bar representing results obtained
with one donor’s cells. (E) The secretion of IFNγ and IL-2 (pg/mL) measured from co-cultures of CAR-transduced T cells and NALM-6
(n = 3). Data from one representative expansion with mean + SD of three replicate measurements are shown. (F) Cytotoxicity of CAR-
transduced T cells incubated with CD19+ SupB-15 B-ALL targets was measured with the calcein release assay. Mean percentages of target
cell lysis in four independent experiments are shown. SDs are omitted for clarity, but ranged from 5%–35%. One-way ANOVA with Tukey
correction for multiple comparisons was used for analysis of cytokine results (E). In IFNγ secretion, P < 0.05 between all other groups
except for 5 vs 20 IU/mL IL-2 (P = not significant [NS]), which is shown for clarity. The Mann-Whitney test was used to calculate sta-
tistical significances for other assays (*P < 0.05).
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degranulation and cytokine secretion assays. Trans-
duction efficiency varied between the three donors,
being 73% (range, 61%–80%), 51% (range, 21%–
66%) and 8% (range, 6%–10%), respectively. In all
of the functionality tests, all CD19-CART cells showed
elevated activity compared with untransduced or
empty-LV transduced T cells (Figure 7C–7E), indi-
cating that the observed CAR T-cell functions were
dependent on CAR expression. The strength of the
anti-B-ALL degranulation, proliferation and cytokine
secretion response varied between the three tested CAR
T-cell expansions, higher response correlating with the
higher proportion of CAR-positive cells
(Figure 7C–7E). In all three expansions and regard-
less of transduction efficiency, the increase of exogenous
IL-2 used for CART-cell production led to more active
degranulation, proliferation and secretion of IL-2 and
IFN-γ in response to target cells (Figure 7C–7E).These
results are in agreement with our finding that higher
IL-2 concentrations duringT-cell expansion yield higher
proportions of more differentiated effector T cells.
Cytotoxic potency was measured using the calcein
release assay. CD19-CAR T-cell products produced
under different IL-2 concentrations all demon-
strated efficient and dose-dependent killing of SupB-
15 and NALM-6 cells (Figure 7F and Supplementary
Figure S4). In addition, CD19-CAR T cells showed
minimal cytotoxicity against the CD19-negative B-cell
line BC-3 (data not shown), and untransduced and
empty-LV transduced T cells showed minimal target
cell lysis (Figure 7F and Supplementary Figure S4),
confirming that the killing was antigen-specific and
dependent on CAR expression. Furthermore, expand-
ing the cells in a high concentration of IL-2 (100 and
300 IU/mL) enhanced the killing of CD19+ target cells
compared with cells grown without IL-2 (Figure 7F;
P < 0.0001 and P < 0.0004, respectively, by a linear
modelling analysis, i.e., analysis of covariance; see sup-
plementary file for details.).
In summary, CD19-CART cells demonstrated ver-
satile in vitro functions, and the observedT-cell response
against B-ALL cells was antigen-specific and depen-
dent on CD19-CAR expression. Moreover, in vitro anti-
leukemia response of CD19-CART cells was enhanced
by the increase of exogenous IL-2 used during T-cell
expansion, a change that also favored effector cell dif-
ferentiation as detected using TM phenotyping.
Dissection for the clinical CD19-CART-cell production
protocol
Determining the best expansion conditions for T cells
is complex (Table II). Furthermore, also the lowest
values in key determinants, not only the average values,
are significant for reproducible and cost-effective manu-
facturing.The appropriate clinical cell dose for CAR
T cells is not known and may depend on the cell phe-
notype in the product. With a target of 2 × 106 cells/
kg patient weight [4,37], we estimate that a 25-fold
cumulative fold expansion in cell number would be
needed to cover all patients. On the other hand, only
a five-fold T-cell expansion has been used as a highly
predictive threshold for successful clinical CAR T-cell
manufacturing [28]. Also, high treatment efficacy with
low toxicity was achieved with only 0.2 × 106 CD19-
CAR T cells/kg with a defined 1:1 CD4:CD8 ratio
[38]. Such cell dosing in our estimations corre-
sponds to a three-fold cell expansion only. The total
yield for early memory T cells (Table II and
Supplementary Figure S5) is pivotal if pure cell popu-
lations, and hence also further cell selection, are
preferred.
We hypothesize that an effectiveT-cell product en-
compasses appropriate subpopulation heterogeneity
providing rapid CD8+ effector functions, CD4+ cells
and early T memory cells. T-cell expansion without
IL-2 supplementation yielded an average of 88% early
TM cells at lowest 83% in 10 days (Table II). The
average T-cell subset composition was 0% TSCM, 55%
TSCM-like, 32% TCM, 10% TEM and 3% TEff. In compar-
ison, 100 IU/mL IL-2, the current standard used for
T-cell expansion, yielded 15%TSCM, 46%TSCM-like, 13%
TCM, 9%TEM and 17%TEff. Both CD4+ and CD8+ cells
were generated, and the cells showed functional potency
in vitro. The lowest expansion level without supple-
mental IL-2 was four-fold but on average 11-fold,
corresponding to cell dosing between 0.2 × 106/kg–
1 × 106/kg. By using 100 IU/mL IL-2, the mean cell
expansion was 60-fold (range, 3–15; Table II), which
would provide cell dosing up to 5 × 106/kg. Dose-
escalation studies are needed to define the T-cell
expansion condition providing the best balance between
T-cell subset composition and sufficient total cell
number.
Discussion
IL-2, as “the T-cell growth factor” has been used ex-
tensively for expansion of T-cells in vitro. Its use has
been challenged in recent years as the role of persis-
tent T-cell memory for the clinical success of cancer
treatment has gained focus. Thus, the impetus to
control effector cell differentiation and memory for-
mation is high.We show here that significant numbers
of less-differentiated memory T cells can be gener-
ated simply by limiting the IL-2 concentration during
cell expansion. Use of higher amounts of IL-2 reduced
the generation of early TM by decreasing central
memory T cells and simultaneously increasing differ-
entiated effectors.
To our knowledge, systematic analysis of IL-2
supplementation for in vitro CART-cell expansion has
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not been reported. Here, we have analyzed the asso-
ciation between IL-2 concentration, expansion kinetics
and memory T-cell formation using the CD3/CD28
microbead protocol forT-cell activation. Our data dem-
onstrate that conditions that predominantly rely on
autonomous IL-2 production (0 and 5 IU/mL) induced
T-cell proliferation for only ~10 days resembling the
expansion kinetics of a normal immune response and
by that time yielded the highest proportions of early
T memory cells. Low IL-2 concentration (20 IU/
mL) still limited cell proliferation to 2 weeks. Higher
IL-2 concentrations, that offered T cells seemingly an
unlimited source of proliferative signals (100 and
300 IU/mL), led to the accumulation of effector cells
already by the tenth day of expansion. One hundred
or 300 IU/mL IL-2 is commonly used for in vitroT-cell
expansion and even higher supplementation is used
for TILs [39,40].Thus, it may be that in vitro condi-
tions that override the natural physiological course of
memory T-cell formation, e.g., high IL-2 concentra-
tion, may not be able to generate a significant memory
cell pool.
In addition to the present study, two publica-
tions have reported in vitro T-cell expansion without
any cytokine supplementation. The first one com-
pared two common CART-cell culturing methods used
in early trials: soluble anti-CD3 with 300 IU/mL IL-2
to CD3/CD28 microbeads without any exogenous IL-2
[13].They showed that the bead-based protocol pro-
duced a younger T-cell phenotype with greater
proliferative capacity and better performance in an in
vivo model. Still, it was not clear if the improved results
were obtained due to the CD28 cosignal, provision
of more physiological activation by bead-bound instead
of soluble antibodies or lack of IL-2 supplementa-
tion. Our results here indicate that omitting IL-2 was
at least partly responsible for the better outcome.The
second report investigated the occasional poor in vitro
expansion potential of T cells derived from patients
with B-cell malignancies [28]; one-fourth of patients
were excluded from a CD19 CAR clinical trial because
of unsuccessfulT-cell expansion. Furthermore, the pres-
ence of naïve or earlyT memory cells (TSCM andTCM)
correlated with successful expansion.Together with our
results, these studies demonstrate that in vitro T-cell
expansion without any cytokine supplementation pro-
vides persistence-related early TM cells with increased
in vivo anti-tumor efficacy both in the pre-clinical and
clinical setting and provides a feasible method for most
patients with B-cell malignancies.
T-cell expansion without IL-2 naturally affected the
final cell numbers. In our material mainly from healthy
donors (two leukemia patients were included), we were
able to improve the cell yield without markedly com-
promising the proportion of less-differentiated memory
cells by slightly elevating the IL-2 to 20 IU/mL.This
improved the mean cell numbers four-fold by day 10
of the expansion. Higher IL-2 concentrations, namely
100 and 300 IU/mL, further increased the mean cell
yield by six-fold compared with expansions relying on
autonomous IL-2 production only. Yet, the expan-
sion efficiency is likely lower with patient-derived cell
material, although such difference was not observed
in this study. Efficient expansion in the absence of IL-2
can also be obtained using IL-7 and IL-15, which was
needed especially for patients with lymphoma [28].
IL-7 and IL-15 have been explored in in vitroT-cell
expansion with a goal to generate early TM. In normal
donors earlyTM or CD45RO+ TSCMs (i.e.,TSCM-like cells)
alone were increased 10%–30% compared with ex-
pansions relying on a high IL-2 concentration (100–
300 IU/mL) [25,27,30]. Here we accomplished an
increase of similar size (5%–30%) in early TM simply
by limiting IL-2 supplementation from the current stan-
dard. Compared with no cytokine supplementation,
IL-7 and IL-15 induced a 10%–20% gain in the
number of TSCMs in products derived from cancer pa-
tients’ cells. Singh et al. also revealed a simultaneous
IL-7 and IL-15–induced decrease in TCM and, inter-
estingly, an increase in TEff [28].TSCM-enriched CAR
T-cell products can also be produced by combining
careful cell selection technology with use of homeo-
static cytokines and signaling inhibitors [32]. To
conclude, our method using a limited amount of IL-2
during T-cell expansion offers a simple, less manipu-
lative and cost-effective alternative for increasing the
proportion of less-differentiated memory T cells.
Among other early TM subsets, we were
able to produce T memory stem cells
(CD95+CD45RO-CD45RA+CD27+). TSCM genera-
tion was not IL-2 dependent. AlthoughTSCMs were not
present in every expansion at a specific time point, each
culture that was analyzed more than once contained
these cells either on day 10 or day 20. Furthermore,
cultures lacking TSCMs on the tenth day of expansion
proliferated poorly during the first week of expan-
sion, possibly linking the presence ofTSCMs to expansion
kinetics. It is somewhat perplexing how a culture
lacking naïve cells and TSCMs, the two least-
differentiated T-cell subsets, can contain TSCMs later
during expansion. However, it is possible that these
subsets were present but below our detection limit.
Also, it is not firmly established if memory T-cell gen-
eration follows the progressive differentiation model
where less-differentiated subsets function as precur-
sors for more differentiated ones [41].
Most in vitro expansion protocols lack the ability
to generateTSCMs but produce so-calledTSCM-like cells
that have gained the expression of CD45RO
[25–27,30].TheTSCM-like population was likewise the
major memory subset present using our expansion pro-
tocol. It is not currently known which of the early T
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memory subsets (TSCM,TSCM-like or TCM) provides the
best clinical efficacy in humans. A certain level of cell
subset heterogeneity can be a good strategy. Thus,
lengthening the expansion time to increase the TSCM
proportion is probably not feasible as the proportion
of total early memory T cells decreases. However,
finding out the factors inducing the generation ofTSCMs
in our system would be of substantial scientific inter-
est. Such factors may also have potential in the
production of adoptive T-cell products.T-cell–derived
natural components may facilitate development of less
manipulative ways to produce TSCM cells. IL-7 may
provide key signals for the formation ofTSCM-like cells
together with IL-15 [25] and of TSCM cells together
with IL-21 and additional modification of intracellu-
lar signaling [32]. IL-7 or IL-15 is not produced by
T cells themselves, but IL-21 and IL-9 are pro-
duced by activated CD4+ T cells [24]. IL-9 supports
T-cell growth during late phases of immune re-
sponses. Interestingly, it also supports anti-tumor
activity and survival of TIL through apoptosis resis-
tance [42].We do not know if the cells in our expansion
protocol produced IL-9 or IL-21. However, knowing
that early TM and CD4+ cells correlate with T-cell per-
sistence in a clinical setting [10] and that CD4+ cells
are a prerequisite for mouse memory T-cell forma-
tion [19,20], it is tempting to hypothesize that CD4+
cells might play a role in TSCM generation. As growth
kinetics played a role, we hypothesize that TSCM gen-
eration is induced by factors produced by CD4+ T cells
after their peak proliferation.
The significance of CD4+ cells was recently dem-
onstrated in a sophisticated CAR T-cell study [14].
The authors postulated that IL-2 produced by CD4+
cells drove the enhanced CD8+ proliferation in vivo
that correlated with efficacy. According to their data,
60% of CD8+ and 75% of CD4+ cells expressed
CD45RO and CD27 and thus represented early TM.
A similar cellular distribution was obtained with our
simplified method in a 10-day expansion using IL-2
at 20–100 IU/mL. Due to the prominent role of
CD4+ T cells in adoptive T-cell therapy, a better
understanding of their optimal proportion and how
expansion conditions impact their numbers in rela-
tion to CD8+ T cells is needed. We show that the
proportion of CD4+ cells is increased if very low or
high concentrations of supplemental IL-2 are used,
but that extending the expansion time from 10 to 20
days leads to the accumulation of CD8+ cells at the
expense of CD4+.
Several studies indicate that improved in vivo per-
formance in humans [9,10] and animal models [11–14]
is achieved with T-cell products that contain early
memory T cells, either TSCM, TSCM-like or TCM. In ad-
dition to memory T-cell phenotyping, we showed that
the cell products expanded under different IL-2 con-
ditions had differences in in vitro function. Although
the tests do not measure persistence, the results dem-
onstrate that the products differ functionally. For these
reasons, even though these studies did not include in
vivo testing, it is reasonable to infer that improved in
vivo performance may be achieved using the cells pro-
duced with low IL-2 supplementation as well.
One more consideration regarding the use of early
memoryT cells in the treatment of cancer remains un-
resolved. Assuming that in vitro–generated early
memoryT cells have a similar homing capacity to their
physiological counterparts [12,15], they will have
limited potential to enter peripheral tissues such as
tumors, and rather home to lymphoid organs for ac-
tivation by antigen-presenting cells. In cancer, the
function of antigen-presenting cells is often sup-
pressed. Thus, early memory cell–enriched T-cell
products may be particularly effective in hemato-
logic malignancies where malignant target cells are
found in lymphoid organs, but less so in solid tumors
lacking lymph node metastasis.
Less-differentiated memory T cells are critical
for clinical anti-tumor efficiency. We demonstrate
that the number of early TM cells in a T-cell prepara-
tion can be increased by simply reducing the IL-2
amount used during in vitro T-cell expansion. In
light of our results, the necessity of sophisticated
multi-step protocols may need re-evaluation. These
findings are significant for robust and cost-effective
clinical T-cell manufacturing.
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